Related to Tekmira to Advance Two Roche RNAi Therapies in $50.4M Deal

• Roche Allies with MGH and Harvard to Develop Stem Cell-Derived Cell Lines for Drug Discovery
  
• Biosearch Licenses Roche IP that Allows the Manufacture and Sale of IVD Kits
  
• Roche Expands Agreement with b3 bio to Include Therapeutic Technologies
  
• Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research
  
• BioInvent and ThromboGenics Earn €10M as Roche Progresses Anticancer Agent
  
• Roche and Biogen Idec Ditch Phase III RA Program with Ocrelizumab
  
• Roche’s RoActemra Eases Symptoms of Systemic Juvenile Idiopathic Arthritis in Phase III Study
  
• Roche and IBM Set Sights on $100–1,000 Genome Nanopore Sequencing Platform
  
• Roche Gains Qiagen’s PI3K Oncogene for Mutation Assay Development
  
• Baylor Genome Center to Sequence 5,000 Exomes Using Roche NimbleGen Capture Technology
  
• Roche to Pay Aileron $25M to Tap Into Stapled Peptide Expertise
  
• Roche and reMynd Partner to Develop Disease-Modifying AD and PD Candidates
  
• Ambry Confirmed as First U.S. CSP for NimbleGen Sequence-Capture Solution
  
• Eurofins to Provide Roche GS Junior for Smaller-Scale Projects
  
• Roche Pays InterMune $175M for Full Global Rights to Phase II-Stage HCV Drug
  
• Biotie Restructures to Focus on Clinical Pipeline Headed by Lundbeck-Partnered Nalmefene
  
• Roche to Leverage Aposense's EarliTest Imaging Tool
  
• Roche Sublicenses EGFR IP from Genzyme to Develop Tarceva Companion Diagnostic
  
• Serodus Licenses Potential Heart Failure Therapy from Roche
  
• Phase III Study Shows Mutation-Specific Metastatic Melanoma Drug Boosts Survival